Cue Biopharma
CUE
45 hedge funds and large institutions have $51.3M invested in Cue Biopharma in 2019 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 6 reducing their positions, and 2 closing their positions.
2,498% more capital inflows, than outflows
Capital inflows: $13.1M | Capital outflows: $505K
400% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 2
250% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 6
22% more funds holding
Funds holding: 37 → 45 (+8)
5.27% more ownership
Funds ownership: 21.66% → 26.93% (+5.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Slate Path Capital
New York
|
+$7.13M |
| 2 |
6CM
683 Capital Management
New York
|
+$2.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.15M |
| 4 |
BlackRock
New York
|
+$586K |
| 5 |
HSBC Holdings
London,
United Kingdom
|
+$546K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$221K |
| 2 |
WealthSource Partners
San Luis Obispo,
California
|
-$119K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$64.4K |
| 4 |
Rock Creek Group
Washington,
District of Columbia
|
-$57.6K |
| 5 |
Citigroup
New York
|
-$20.7K |
CUE Hedge Fund Activity: Q3 2019 in Review
45 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q3 2019, worth a combined $51.3M — up 27% from $40.5M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CUE positions and 2 closed out — a net gain of 8 holders — while 21 added to existing stakes and 6 trimmed.
The largest buyer was Slate Path Capital, opening a new position worth an estimated $7.13M. The largest seller was State of Wisconsin Investment Board, exiting entirely with an estimated $221K sold.
- 45 institutional investors held Cue Biopharma (CUE) as of Q3 2019, up from 37 in Q2 2019.
- Funds reported $51.3M of Cue Biopharma stock for Q3 2019, up 27% quarter-over-quarter.
- 10 funds opened new Cue Biopharma positions in Q3 2019 and 2 closed out, a net change of +8 holders.
- The largest Cue Biopharma buyer in Q3 2019 was Slate Path Capital, an estimated $7.13M added.
- The largest Cue Biopharma seller in Q3 2019 was State of Wisconsin Investment Board, an estimated $221K sold.
Based on aggregated 13F filings for Q3 2019.